Is inflammation the cause of pre-eclampsia?

Biochemical Society Transactions

Volumn 39, Issue 6, 2011, Pages 1619-1627

  Ramma, Wenda ^a   Ahmed, Asif ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Cytokine; Inflammation; Pre eclampsia; Soluble endoglin (sEng); Soluble Fms like tyrosine kinase receptor 1 (sFlt 1); Vascular endothelial growth factor (VEGF)

Indexed keywords

BETAMETHASONE; CORTICOSTEROID; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; APHERESIS; APOPTOSIS; BLOOD VESSEL TONE; COMPLEMENT SYSTEM; CONFERENCE PAPER; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG MEGADOSE; ENDOTHELIAL DYSFUNCTION; HELLP SYNDROME; HIGH RISK PREGNANCY; HUMAN; HYPERTENSION; IMMUNE DEFICIENCY; INFLAMMATION; INTRAUTERINE GROWTH RETARDATION; LEUKOCYTE ACTIVATION; MATERNAL HYPERTENSION; NONHUMAN; PATHOGENESIS; PREECLAMPSIA; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); TH1 CELL; TH2 CELL;

ANIMALS; FEMALE; HUMANS; INFLAMMATION; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PATHOLOGIC; PRE-ECLAMPSIA; PREGNANCY;

EID: 81855218052     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST20110672     Document Type: Conference Paper

References (121)

1. World Health Organization (2005) Make Every Mother and Child Count: the World Health Report 2005, p. 63, WHO, Geneva
2. Dekker, G.A. and Sibai, B.M. (1998) Etiology and pathogenesis of preeclampsia: current concepts. Am. J. Obstet. Gynecol. 179, 1359-1375 (Pubitemid 28533800)
3. Ahmed, A. (2011) New insights into the etiology of preeclampsia: identification of key elusive factors for the vascular complications. Thromb. Res. 127 (Suppl. 3), S72-S75
4. Cooke, J.P., Dzau, J. and Creager, A. (1991) Endothelial dysfunction in hypercholesterolemia is corrected by l-arginine. Basic Res. Cardiol. 86 (Suppl. 2), 173-181
5. Bivalacqua, T.J., Usta, M.F., Champion, H.C., Kadowitz, P.J. and Hellstrom, W.J. (2003) Endothelial dysfunction in erectile dysfunction: role of the endothelium in erectile physiology and disease. J. Androl. 24, S17-S37 (Pubitemid 37370524)
6. Roberts, J.M. and Redman, C.W. (1993) Pre-eclampsia: more than pregnancy-induced hypertension. Lancet 341, 1447-1451 (Pubitemid 23161452)
7. Roberts, J.M., Taylor, R.N., Musci, T.J., Rodgers, G.M., Hubel, C.A. and McLaughlin, M.K. (1989) Preeclampsia: an endothelial cell disorder. Am. J. Obstet. Gynecol. 161, 1200-1204 (Pubitemid 20007682)
8. Redman, C.W., Sacks, G.P. and Sargent, I.L. (1999) Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am. J. Obstet. Gynecol. 180, 499-506 (Pubitemid 29093892)
9. Ahmed, A. (1997) Heparin-binding angiogenic growth factors in pregnancy. Trophoblast Res. 10, 215-258
10. Maynard, S.E., Min, J.Y., Merchan, J., Lim, K.H., Li, J., Mondal, S., Libermann, T.A., Morgan, J.P., Sellke, F.W., Stillman, I.E. et al. (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 111, 649-658
11. Venkatesha, S., Toporsian, M., Lam, C., Hanai, J., Mammoto, T., Kim, Y.M., Bdolah, Y., Lim, K.H., Yuan, H.T., Libermann, T.A. et al. (2006) Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat. Med. 12, 642-649 (Pubitemid 43865232)
12. Levine, R.J., Thadhani, R., Qian, C., Lam, C., Lim, K.H., Yu, K.F., Blink, A.L., Sachs, B.P., Epstein, F.H., Sibai, B.M. et al. (2005) Urinary placental growth factor and risk of preeclampsia. JAMA, J. Am. Med. Assoc. 293, 77-85 (Pubitemid 40066702)
13. Ahmed, A., Rahman, M., Zhang, X., Acevedo, C.H., Nijjar, S., Rushton, I., Bussolati, B. and St John, J. (2000) Induction of placental heme oxygenase-1 is protective against TNFα-induced cytotoxicity and promotes vessel relaxation. Mol. Med. 6, 391-409
14. Cudmore, M., Ahmad, S., Al-Ani, B., Fujisawa, T., Coxall, H., Chudasama, K., Devey, L.R., Wigmore, S.J., Abbas, A., Hewett, P.W. and Ahmed, A. (2007) Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. Circulation 115, 1789-1797 (Pubitemid 46648616)
15. Cudmore, M.J., Ahmad, S., Sissaoui, S., Ramma, W., Ma, B., Fujisawa, T., Al-Ani, B., Wang, K., Cai, M., Crispi, F. et al. (2011) Loss of Akt activity increases circulating soluble endoglin release in preeclampsia: identification of inter-dependency between Akt-1 and heme oxygenase-1. Eur. Heart J., doi:10.1093/eurheartj/ehr065
16. Burton, G.J., Woods, A.W., Jauniaux, E. and Kingdom, J.C. (2009) Rheological and physiological consequences of conversion of the maternal spiral arteries for uteroplacental blood flow during human pregnancy. Placenta 30, 473-482
17. Redman, C.W. and Sargent, I.L. (2010) Immunology of pre-eclampsia. Am. J. Reprod. Immunol. 63, 534-543
18. Ayuk, P.T. and Matijevic, R. (2006) Placental ischaemia is a consequence rather than a cause of pre-eclampsia. Med. Hypotheses 67, 792-795 (Pubitemid 44062140)
19. Willis, C., Morris, J.M., Danis, V. and Gallery, E.D. (2003) Cytokine production by peripheral blood monocytes during the normal human ovulatory menstrual cycle. Hum. Reprod. 18, 1173-1178 (Pubitemid 36740560)
20. Vuorela, P., Helske, S., Hornig, C., Alitalo, K., Weich, H. and Halmesmaki, E. (2000) Amniotic fluid-soluble vascular endothelial growth factor receptor-1 in preeclampsia. Obstet. Gynecol. 95, 353-357 (Pubitemid 30100498)
21. Ahmad, S. and Ahmed, A. (2001) Regulation of soluble VEGFR-1 by VEGF and oxygen and its elevation in pre-eclampsia and fetal growth restriction. Placenta 22, A7
22. Kabbinavar, F., Hurwitz, H.I., Fehrenbacher, L., Meropol, N.J., Novotny, W.F., Lieberman, G., Griffing, S. and Bergsland, E. (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. 21, 60-65
23. Levine, R.J., Maynard, S.E., Qian, C., Lim, K.H., England, L.J., Yu, K.F., Schisterman, E.F., Thadhani, R., Sachs, B.P., Epstein, F.H. et al. (2004) Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 350, 672-683 (Pubitemid 38364626)
24. Bergmann, A., Ahmad, S., Cudmore, M., Gruber, A.D., Wittschen, P., Lindenmaier, W., Christofori, G., Gross, V., Gonzalves, A., Grone, H.J. et al. (2010) Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model. J. Cell. Mol. Med. 14, 1857-1867
25. Costantine, M.M., Tamayo, E., Lu, F., Bytautiene, E., Longo, M., Hankins, G.D. and Saade, G.R. (2010) Using pravastatin to improve the vascular reactivity in a mouse model of soluble fms-like tyrosine kinase-1-induced preeclampsia. Obstet. Gynecol. 116, 114-120
26. Ahmad, S. and Ahmed, A. (2004) Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ. Res. 95, 884-891 (Pubitemid 39435003)
27. Ahmad, S., Hewett, P.W., Al-Ani, B., Sissaoui, S., Fujisawa, T., Cudmore, M.J. and Ahmed, A. (2011) Autocrine activity of soluble Flt-1 controls endothelial cell function and angiogenesis. Vasc. Cell 3, 15
28. Ahmed, A. and Cudmore, M.J. (2009) Can the biology of VEGF and haem oxygenases help solve pre-eclampsia? Biochem. Soc. Trans. 37, 1237-1242
29. Foidart, J.M., Schaaps, J.P., Chantraine, F., Munaut, C. and Lorquet, S. (2009) Dysregulation of anti-angiogenic agents (sFlt-1, PLGF, and sEndoglin) in preeclampsia: a step forward but not the definitive answer. J. Reprod. Immunol. 82, 106-111
30. Ahmed, A., Dunk, C., Kniss, D. and Wilkes, M. (1997) Role of VEGF receptor-1 (Flt-1) in mediating calcium-dependent nitric oxide release and limiting DNA synthesis in human trophoblast cells. Lab. Invest. 76, 779-791 (Pubitemid 27260345)
31. Papapetropoulos, A., Garcia-Cardena, G., Madri, J.A. and Sessa, W.C. (1997) Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J. Clin. Invest. 100, 3131-3139 (Pubitemid 28022851)
32. Khaliq, A., Dunk, C., Jiang, J., Shams, M., Li, X.F., Acevedo, C., Weich, H., Whittle, M. and Ahmed, A. (1999) Hypoxia down-regulates placenta growth factor, whereas fetal growth restriction up-regulates placenta growth factor expression: molecular evidence for "placental hyperoxia" in intrauterine growth restriction. Lab. Invest. 79, 151-170 (Pubitemid 29110646)
33. Bussolati, B., Dunk, C., Grohman, M., Kontos, C.D., Mason, J. and Ahmed, A. (2001) Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide. Am. J. Pathol. 159, 993-1008 (Pubitemid 32847190)
34. Jerkic, M., Rivas-Elena, J.V., Prieto, M., Carron, R., Sanz-Rodriguez, F., Perez-Barriocanal, F., Rodriguez-Barbero, A., Bernabeu, C. and Lopez-Novoa, J.M. (2004) Endoglin regulates nitric oxide-dependent vasodilatation. FASEB J. 18, 609-611
35. Toporsian, M., Gros, R., Kabir, M.G., Vera, S., Govindaraju, K., Eidelman, D.H., Husain, M. and Letarte, M. (2005) A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia. Circ. Res. 96, 684-692 (Pubitemid 40478336)
36. Zimmerman, G.A., Prescott, S.M. and McIntyre, T.M. (1992) Endothelial cell interactions with granulocytes: tethering and signaling molecules. Immunol. Today 13, 93-100
37. Mantovani, A. and Dejana, E. (1989) Cytokines as communication signals between leukocytes and endothelial cells. Immunol. Today 10, 370-375 (Pubitemid 19242062)
38. Greer, I.A., Dawes, J., Johnston, T.A. and Calder, A.A. (1991) Neutrophil activation is confined to the maternal circulation in pregnancy-induced hypertension. Obstet. Gynecol. 78, 28-32
39. Prieto, J.A., Panyutich, A.V. and Heine, R.P. (1997) Neutrophil activation in preeclampsia. Are defensins and lactoferrin elevated in preeclamptic patients? J. Reprod. Med. 42, 29-32 (Pubitemid 27053449)
40. Holthe, M.R., Staff, A.C., Berge, L.N., Fagerhol, M.K. and Lyberg, T. (2005) Calprotectin plasma level is elevated in preeclampsia. Acta Obstet. Gynecol. Scand. 84, 151-154 (Pubitemid 40278803)
41. Braekke, K., Holthe, M.R., Harsem, N.K., Fagerhol, M.K. and Staff, A.C. (2005) Calprotectin, a marker of inflammation, is elevated in the maternal but not in the fetal circulation in preeclampsia. Am. J. Obstet. Gynecol. 193, 227-233 (Pubitemid 40991850)
42. Belo, L., Santos-Silva, A., Caslake, M., Cooney, J., Pereira-Leite, L., Quintanilha, A. and Rebelo, I. (2003) Neutrophil activation and C-reactive protein concentration in preeclampsia. Hypertens. Pregnancy 22, 129-141 (Pubitemid 37521364)
43. Lynch, A.M., Murphy, J.R., Gibbs, R.S., Levine, R.J., Giclas, P.C., Salmon, J.E. and Holers, V.M. (2010) The interrelationship of complement-activation fragments and angiogenesis-related factors in early pregnancy and their association with pre-eclampsia. BJOG 117, 456-462
44. Mosmann, T.R. and Sad, S. (1996) The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol. Today 17, 138-146 (Pubitemid 26074503)
45. Wegmann, T.G., Lin, H., Guilbert, L. and Mosmann, T.R. (1993) Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? Immunol. Today 14, 353-356 (Pubitemid 23198169)
46. Saito, S., Sakai, M., Sasaki, Y., Tanebe, K., Tsuda, H. and Michimata, T. (1999) Quantitative analysis of peripheral blood Th0, Th1, Th2 and the Th1:Th2 cell ratio during normal human pregnancy and preeclampsia. Clin. Exp. Immunol. 117, 550-555 (Pubitemid 29398304)
47. Orange, S., Horvath, J. and Hennessy, A. (2003) Preeclampsia is associated with a reduced interleukin-10 production from peripheral blood mononuclear cells. Hypertens. Pregnancy 22, 1-8 (Pubitemid 36205803)
48. Holthe, M.R., Staff, A.C., Berge, L.N. and Lyberg, T. (2004) Leukocyte adhesion molecules and reactive oxygen species in preeclampsia. Obstet. Gynecol. 103, 913-922 (Pubitemid 40458992)
49. Szarka, A., Rigo, J., Jr., Lazar, L., Beko, G. and Molvarec, A. (2010) Circulating cytokines, chemokines and adhesion molecules in normal pregnancy and preeclampsia determined by multiplex suspension array. BMC Immunol. 11, 59
50. Hill, A.B. (1965) The environment and disease: association or causation? Proc. R. Soc. Med. 58, 295-300
51. Levine, R.J., Lam, C., Qian, C., Yu, K.F., Maynard, S.E., Sachs, B.P., Sibai, B.M., Epstein, F.H., Romero, R., Thadhani, R. and Karumanchi, S.A. (2006) Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N. Engl. J. Med. 355, 992-1005 (Pubitemid 44343543)
52. Chaiworapongsa, T., Romero, R., Kim, Y.M., Kim, G.J., Kim, M.R., Espinoza, J., Bujold, E., Gonçalves, L., Gomez, R., Edwin, S. and Mazor, M. (2005) Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J. Matern. Fetal Neonatal Med. 17, 3-18 (Pubitemid 40515938)
53. Rana, S., Karumanchi, S.A., Levine, R.J., Venkatesha, S., Rauh-Hain, J.A., Tamez, H. and Thadhani, R. (2007) Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension 50, 137-142 (Pubitemid 46986022)
54. Romero, R., Nien, J.K., Espinoza, J., Todem, D., Fu, W., Chung, H., Kusanovic, J.P., Gotsch, F., Erez, O., Mazaki-Tovi, S. et al. (2008) A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J. Matern. Fetal Neonatal Med. 21, 9-23
55. Erez, O., Romero, R., Espinoza, J., Fu, W., Todem, D., Kusanovic, J.P., Gotsch, F., Edwin, S., Nien, J.K., Chaiworapongsa, T. et al. (2008) The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J. Matern. Fetal Neonatal Med. 21, 279-287 (Pubitemid 351652513)
56. Baumann, M.U., Bersinger, N.A., Mohaupt, M.G., Raio, L., Gerber, S. and Surbek, D.V. (2008) First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia. Am. J. Obstet. Gynecol. 199, 266.e1-266.e6
57. Lim, J.H., Kim, S.Y., Park, S.Y., Lee, M.H., Yang, J.H., Kim, M.Y., Chung, J.H., Lee, S.W. and Ryu, H.M. (2009) Soluble endoglin and transforming growth factor-β1 in women who subsequently developed preeclampsia. Prenatal Diagn. 29, 471-476
58. Foidart, J.M., Munaut, C., Chantraine, F., Akolekar, R. and Nicolaides, K.H. (2010) Maternal plasma soluble endoglin at 11-13 weeks'gestation in pre-eclampsia. Ultrasound Obstet. Gynecol. 35, 680-687
59. Barden, A., Graham, D., Beilin, L.J., Ritchie, J., Baker, R., Walters, B.N. and Michael, C.A. (1997) Neutrophil CD11B expression and neutrophil activation in pre-eclampsia. Clin. Sci. 92, 37-44 (Pubitemid 27033008)
60. Peracoli, J.C., Rudge, M.V. and Peracoli, M.T. (2007) Tumor necrosis factor-α in gestation and puerperium of women with gestational hypertension and pre-eclampsia. Am. J. Reprod. Immunol. 57, 177-185 (Pubitemid 46231935)
61. Greer, I.A., Lyall, F., Perera, T., Boswell, F. and Macara, L.M. (1994) Increased concentrations of cytokines interleukin-6 and interleukin-1 receptor antagonist in plasma of women with preeclampsia: a mechanism for endothelial dysfunction? Obstet. Gynecol. 84, 937-940 (Pubitemid 24360251)
62. Hayakawa, S., Fujikawa, T., Fukuoka, H., Chisima, F., Karasaki-Suzuki, M., Ohkoshi, E., Ohi, H., Kiyoshi Fujii, T., Tochigi, M., Satoh, K. et al. (2000) Murine fetal resorption and experimental pre-eclampsia are induced by both excessive Th1 and Th2 activation. J. Reprod. Immunol. 47, 121-138 (Pubitemid 30621431)
63. Djurovic, S., Clausen, T., Wergeland, R., Brosstad, F., Berg, K. and Henriksen, T. (2002) Absence of enhanced systemic inflammatory response at 18 weeks of gestation in women with subsequent pre-eclampsia. BJOG 109, 759-764 (Pubitemid 37329250)
64. Kronborg, C.S., Gjedsted, J., Vittinghus, E., Hansen, T.K., Allen, J. and Knudsen, U.B. (2011) Longitudinal measurement of cytokines in pre-eclamptic and normotensive pregnancies. Acta Obstet. Gynecol. Scand. 90, 791-796
65. Lynch, A.M., Murphy, J.R., Byers, T., Gibbs, R.S., Neville, M.C., Giclas, P.C., Salmon, J.E. and Holers, V.M. (2008) Alternative complement pathway activation fragment Bb in early pregnancy as a predictor of preeclampsia. Am. J. Obstet. Gynecol. 198, 385.e1-385.e9
66. Noori, M., Donald, A.E., Angelakopoulou, A., Hingorani, A.D. and Williams, D.J. (2010) Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension. Circulation 122, 478-487
67. Buhimschi, C.S., Baumbusch, M.A., Dulay, A.T., Lee, S., Wehrum, M., Zhao, G., Bahtiyar, M.O., Pettker, C.M., Ali, U.A., Funai, E.F. and Buhimschi, I.A. (2010) The role of urinary soluble endoglin in the diagnosis of pre-eclampsia: comparison with soluble fms-like tyrosine kinase 1 to placental growth factor ratio. BJOG 117, 321-330
68. Jonsson, Y., Ruber, M., Matthiesen, L., Berg, G., Nieminen, K., Sharma, S., Ernerudh, J. and Ekerfelt, C. (2006) Cytokine mapping of sera from women with preeclampsia and normal pregnancies. J. Reprod. Immunol. 70, 83-91
69. Sharma, A., Satyam, A. and Sharma, J.B. (2007) Leptin, IL-10 and inflammatory markers (TNF-α, IL-6 and IL-8) in pre-eclamptic, normotensive pregnant and healthy non-pregnant women. Am. J. Reprod. Immunol. 58, 21-30 (Pubitemid 46939024)
70. Kaleli, I., Kaleli, B., Demir, M., Yildirim, B., Cevahir, N. and Demir, S. (2005) Serum levels of neopterin and interleukin-2 receptor in women with severe preeclampsia. J. Clin. Lab. Anal. 19, 36-39 (Pubitemid 40389480)
71. Bachmayer, N., Rafik Hamad, R., Liszka, L., Bremme, K. and Sverremark-Ekstrom, E. (2006) Aberrant uterine natural killer (NK)-cell expression and altered placental and serum levels of the NK-cell promoting cytokine interleukin-12 in pre-eclampsia. Am. J. Reprod. Immunol. 56, 292-301 (Pubitemid 44669325)
72. Freeman, D.J., McManus, F., Brown, E.A., Cherry, L., Norrie, J., Ramsay, J.E., Clark, P., Walker, I.D., Sattar, N. and Greer, I.A. (2004) Short- and long-term changes in plasma inflammatory markers associated with preeclampsia. Hypertension 44, 708-714 (Pubitemid 39435242)
73. Mihu, D., Costin, N., Mihu, C.M., Blaga, L.D. and Pop, R.B. (2008) C-reactive protein, marker for evaluation of systemic inflammatory response in preeclampsia. Rev. Med. Chir. Soc. Med. Nat. Iasi 112, 1019-1025
74. D'Anna, R., Baviera, G., Giordano, D., Todarello, G., Corrado, F. and Buemi, M. (2008) Second trimester neutrophil gelatinase-associated lipocalin as a potential prediagnostic marker of preeclampsia. Acta Obstet. Gynecol. Scand. 87, 1370-1373
75. Bdolah, Y., Lam, C., Rajakumar, A., Shivalingappa, V., Mutter, W., Sachs, B.P., Lim, K.H., Bdolah-Abram, T., Epstein, F.H. and Karumanchi, S.A. (2008) Twin pregnancy and the risk of preeclampsia: bigger placenta or relative ischemia? Am. J. Obstet. Gynecol. 198, 428.e1-428.e6
76. Powers, R.W., Jeyabalan, A., Clifton, R.G., Van Dorsten, P., Hauth, J.C., Klebanoff, M.A., Lindheimer, M.D., Sibai, B., Landon, M. and Miodovnik, M. (2010) Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies. PLoS ONE 5, e13263
77. Buhimschi, C.S., Magloire, L., Funai, E., Norwitz, E.R., Kuczynski, E., Martin, R., Richman, S., Guller, S., Lockwood, C.J. and Buhimschi, I.A. (2006) Fractional excretion of angiogenic factors in women with severe preeclampsia. Obstet. Gynecol. 107, 1103-1113
78. Wallner, W., Sengenberger, R., Strick, R., Strissel, P.L., Meurer, B., Beckmann, M.W. and Schlembach, D. (2007) Angiogenic growth factors in maternal and fetal serum in pregnancies complicated by intrauterine growth restriction. Clin. Sci. 112, 51-57 (Pubitemid 46120085)
79. Makris, A., Thornton, C., Thompson, J., Thomson, S., Martin, R., Ogle, R., Waugh, R., McKenzie, P., Kirwan, P. and Hennessy, A. (2007) Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. Kidney Int. 71, 977-984 (Pubitemid 46741987)
80. Roberts, L., LaMarca, B.B., Fournier, L., Bain, J., Cockrell, K. and Granger, J.P. (2006) Enhanced endothelin synthesis by endothelial cells exposed to sera from pregnant rats with decreased uterine perfusion. Hypertension 47, 615-618 (Pubitemid 43843885)
81. Agunanne, E.E., Uddin, M.N., Horvat, D. and Puschett, J.B. (2010) Contribution of angiogenic factors in a rat model of pre-eclampsia. Am. J. Nephrol. 32, 332-339
82. Lu, F., Longo, M., Tamayo, E., Maner, W., Al-Hendy, A., Anderson, G.D., Hankins, G.D. and Saade, G.R. (2007) The effect of over-expression of sFlt-1 on blood pressure and the occurrence of other manifestations of preeclampsia in unrestrained conscious pregnant mice. Am. J. Obstet. Gynecol. 196, 396.e1-396.e7
83. Gilbert, J.S., Babcock, S.A. and Granger, J.P. (2007) Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 expression. Hypertension 50, 1142-1147 (Pubitemid 350172938)
84. Li, Z., Zhang, Y., Ying Ma, J., Kapoun, A.M., Shao, Q., Kerr, I., Lam, A., O'Young, G., Sannajust, F., Stathis, P. et al. (2007) Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension 50, 686-692 (Pubitemid 47442732)
85. Bytautiene, E., Lu, F., Tamayo, E.H., Hankins, G.D., Longo, M., Kublickiene, K. and Saade, G.R. (2010) Long-term maternal cardiovascular function in a mouse model of sFlt-1-induced preeclampsia. Am. J. Physiol. Heart Circ. Physiol. 298, H189-H193
86. Suzuki, H., Ohkuchi, A., Matsubara, S., Takei, Y., Murakami, M., Shibuya, M., Suzuki, M. and Sato, Y. (2009) Effect of recombinant placental growth factor 2 on hypertension induced by full-length mouse soluble fms-like tyrosine kinase 1 adenoviral vector in pregnant mice. Hypertension 54, 1129-1135
87. Thadhani, R., Kisner, T., Hagmann, H., Bossung, V., Noack, S., Schaarschmidt, W., Jank, A., Kribs, A., Cornely, O.A., Kreyssig, C. et al. (2011) Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation 124, 940-950
88. Faas, M.M., Schuiling, G.A., Baller, J.F., Visscher, C.A. and Bakker, W.W. (1994) A new animal model for human preeclampsia: ultra-low-dose endotoxin infusion in pregnant rats. Am. J. Obstet. Gynecol. 171, 158-164 (Pubitemid 24254435)
89. Zenclussen, A.C., Fest, S., Joachim, R., Klapp, B.F. and Arck, P.C. (2004) Introducing a mouse model for pre-eclampsia: adoptive transfer of activated Th1 cells leads to pre-eclampsia-like symptoms exclusively in pregnant mice. Eur. J. Immunol. 34, 377-387 (Pubitemid 39255948)
90. Elmarakby, A.A., Quigley, J.E., Imig, J.D., Pollock, J.S. and Pollock, D.M. (2008) TNF-α inhibition reduces renal injury in DOCA-salt hypertensive rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 294, R76-R83
91. Guzik, T.J., Hoch, N.E., Brown, K.A., McCann, L.A., Rahman, A., Dikalov, S., Goronzy, J., Weyand, C. and Harrison, D.G. (2007) Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J. Exp. Med. 204, 2449-2460 (Pubitemid 47529329)
92. Tinsley, J.H., Chiasson, V.L., South, S., Mahajan, A. and Mitchell, B.M. (2009) Immunosuppression improves blood pressure and endothelial function in a rat model of pregnancy-induced hypertension. Am. J. Hypertens. 22, 1107-1114
93. Zhou, C.C., Irani, R.A., Dai, Y., Blackwell, S.C., Hicks, M.J., Ramin, S.M., Kellems, R.E. and Xia, Y. (2011) Autoantibody-mediated IL-6-dependent endothelin-1 elevation underlies pathogenesis in a mouse model of preeclampsia. J. Immunol. 186, 6024-6034
94. Amorim, M.M., Santos, L.C. and Faundes, A. (1999) Corticosteroid therapy for prevention of respiratory distress syndrome in severe preeclampsia. Am. J. Obstet. Gynecol. 180, 1283-1288 (Pubitemid 29259030)
95. Fonseca, J.E., Mendez, F., Catano, C. and Arias, F. (2005) Dexamethasone treatment does not improve the outcome of women with HELLP syndrome: a double-blind, placebo-controlled, randomized clinical trial. Am. J. Obstet. Gynecol. 193, 1591-1598 (Pubitemid 41540453)
96. Ferrara, N. (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 25, 581-611
97. Esser, S., Wolburg, K., Wolburg, H., Breier, G., Kurzchalia, T. and Risau, W. (1998) Vascular endothelial growth factor induces endothelial fenestrations in vitro. J. Cell Biol. 140, 947-959 (Pubitemid 28141231)
98. Murohara, T., Asahara, T., Silver, M., Bauters, C., Masuda, H., Kalka, C., Kearney, M., Chen, D., Symes, J.F., Fishman, M.C. et al. (1998) Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J. Clin. Invest. 101, 2567-2578 (Pubitemid 28270451)
99. Bussolati, B., Dunk, C., Grohman, M., Kontos, C.D., Mason, J. and Ahmed, A. (2001) Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide. Am. J. Pathol. 159, 993-1008 (Pubitemid 32847190)
100. Kroll, J. and Waltenberger, J. (1999) A novel function of VEGF receptor-2 (KDR): rapid release of nitric oxide in response to VEGF-A stimulation in endothelial cells. Biochem. Biophys. Res. Commun. 265, 636-639
101. Ahmad, S., Hewett, P.W., Wang, P., Al-Ani, B., Cudmore, M., Fujisawa, T., Haigh, J.J., le Noble, F., Wang, L., Mukhopadhyay, D. and Ahmed, A. (2006) Direct evidence for endothelial vascular endothelial growth factor receptor-1 function in nitric oxide-mediated angiogenesis. Circ. Res. 99, 715-722 (Pubitemid 44498305)
102. Cudmore, M., Ahmad, S., Al-Ani, B., Hewett, P., Ahmed, S. and Ahmed, A. (2006) VEGF-E activates endothelial nitric oxide synthase to induce angiogenesis via cGMP and PKG-independent pathways. Biochem. Biophys. Res. Commun. 345, 1275-1282 (Pubitemid 43833439)
103. He, H., Venema, V.J., Gu, X., Venema, R.C., Marrero, M.B. and Caldwell, R.B. (1999) Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src. J. Biol. Chem. 274, 25130-25135
104. Kang, D.H., Kim, Y.G., Andoh, T.F., Gordon, K.L., Suga, S., Mazzali, M., Jefferson, J.A., Hughes, J., Bennett, W., Schreiner, G.F. and Johnson, R.J. (2001) Post-cyclosporine-mediated hypertension and nephropathy: amelioration by vascular endothelial growth factor. Am. J. Physiol. Renal Physiol. 280, F727-F736
105. Eremina, V. and Quaggin, S.E. (2004) The role of VEGF-A in glomerular development and function. Curr. Opin. Nephrol. Hypertens. 13, 9-15 (Pubitemid 39069893)
106. Ostendorf, T., Kunter, U., Eitner, F., Loos, A., Regele, H., Kerjaschki, D., Henninger, D.D., Janjic, N. and Floege, J. (1999) VEGF165 mediates glomerular endothelial repair. J. Clin. Invest. 104, 913-923 (Pubitemid 29536341)
107. Masuda, Y., Shimizu, A., Mori, T., Ishiwata, T., Kitamura, H., Ohashi, R., Ishizaki, M., Asano, G., Sugisaki, Y. and Yamanaka, N. (2001) Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis. Am. J. Pathol. 159, 599-608 (Pubitemid 32751090)
108. Kim, Y.G., Suga, S.I., Kang, D.H., Jefferson, J.A., Mazzali, M., Gordon, K.L., Matsui, K., Breiteneder-Geleff, S., Shankland, S.J., Hughes, J. et al. (2000) Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy. Kidney Int. 58, 2390-2399
109. Sugimoto, H., Hamano, Y., Charytan, D., Cosgrove, D., Kieran, M., Sudhakar, A. and Kalluri, R. (2003) Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J. Biol. Chem. 278, 12605-12608 (Pubitemid 36800018)
110. Saito, S., Shiozaki, A., Nakashima, A., Sakai, M. and Sasaki, Y. (2007) The role of the immune system in preeclampsia. Mol. Aspects Med. 28, 192-209 (Pubitemid 46843191)
111. Poston, L. (2006) Endothelial dysfunction in pre-eclampsia. Pharmacol. Rep. 58 (Suppl.), 69-74
112. LaMarca, B.B., Cockrell, K., Sullivan, E., Bennett, W. and Granger, J.P. (2005) Role of endothelin in mediating tumor necrosis factor-induced hypertension in pregnant rats. Hypertension 46, 82-86 (Pubitemid 40946495)
113. Collino, F., Bussolati, B., Gerbaudo, E., Marozio, L., Pelissetto, S., Benedetto, C. and Camussi, G. (2008) Preeclamptic sera induce nephrin shedding from podocytes through endothelin-1 release by endothelial glomerular cells. Am. J. Physiol. Renal Physiol. 294, F1185-F1194
114. Cindrova-Davies, T., Sanders, D.A., Burton, G.J. and Charnock-Jones, D.S. (2011) Soluble FLT1 sensitizes endothelial cells to inflammatory cytokines by antagonizing VEGF receptor-mediated signalling. Cardiovasc. Res. 89, 671-679
115. Sibai, B., Dekker, G. and Kupferminc, M. (2005) Pre-eclampsia. Lancet 365, 785-799 (Pubitemid 40311367)
116. Sibai, B.M., Ewell, M., Levine, R.J., Klebanoff, M.A., Esterlitz, J., Catalano, P.M., Goldenberg, R.L. and Joffe, G. (1997) Risk factors associated with preeclampsia in healthy nulliparous women: the Calcium for Preeclampsia Prevention (CPEP) Study Group. Am. J. Obstet. Gynecol. 177, 1003-1010 (Pubitemid 27525346)
117. Duckitt, K. and Harrington, D. (2005) Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. Br. Med. J. 330, 565
118. Catov, J.M., Bodnar, L.M., Ness, R.B., Barron, S.J. and Roberts, J.M. (2007) Inflammation and dyslipidemia related to risk of spontaneous preterm birth. Am. J. Epidemiol. 166, 1312-1319 (Pubitemid 350129427)
119. Giannakopoulos, B., Passam, F., Ioannou, Y. and Krilis, S.A. (2009) How we diagnose the antiphospholipid syndrome. Blood 113, 985-994
120. Hanly, J.G. (2003) Antiphospholipid syndrome: an overview. Can. Med. Assoc. J. 168, 1675-1682
121. Maynard, S.E. and Karumanchi, S.A. (2011) Angiogenic factors and preeclampsia. Semin. Nephrol. 31, 33-46